Matrix Trust Company’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.39M Buy
2,931
+275
+10% +$324K 0.49% 31
2026
Q2
$3.19M Buy
2,656
+512
+24% +$523K 0.46% 29
2026
Q1
$1.97M Sell
2,144
-61
-3% -$61.8K 0.33% 41
2025
Q4
$2.37M Buy
2,205
+1,545
+234% +$1.48M 0.39% 32
2025
Q3
$504K Buy
660
+222
+51% +$165K 0.08% 91
2025
Q2
$341K Buy
438
+171
+64% +$133K 0.05% 109
2025
Q1
$221K Buy
267
+55
+26% +$45.8K 0.04% 120
2024
Q4
$164K Buy
+212
New +$176K 0.03% 113

Other funds holding LLY

Matrix Trust Company's LLY Position: Q3 2026 in Review

Matrix Trust Company increased its Eli Lilly (LLY) stake by 10% in Q3 2026, buying an estimated $324K and bringing the position to 2,931 shares worth $3.39M. The position accounts for 0.49% of the portfolio, ranked #31.

Matrix Trust Company first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 2,846 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Matrix Trust Company held 2,931 shares of Eli Lilly worth $3.39M as of Q3 2026.
  • Matrix Trust Company bought 275 Eli Lilly shares in Q3 2026, an estimated $324K.
  • Eli Lilly made up 0.49% of Matrix Trust Company's portfolio in Q3 2026, its #31 holding.
  • Matrix Trust Company first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 2,846 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Matrix Trust Company's 13F filing for Q3 2026, filed 7 Oct 2026.